Israel's Gamida Cell raises $40 million for bone marrow trial | | TEL AVIV (Reuters) - Israel's Gamida Cell, which is developing cellular therapies to treat cancer and rare genetic diseases, said on Monday it raised $40 million to finance the advanced trial of its product NiCord to facilitate bone marrow transplants. |
| |
Novartis throws down gauntlet to Roche with Rituxan copy | | ZURICH (Reuters) - Switzerland's Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases. |
| |
| | |